Accelerated bookbuild offering Biocartis

Kempen is proud to announce that it acted as Joint Bookrunner in the €80 million capital increase by Biocartis.

BIOCARTIS

Biocartis is an innovative commercial stage molecular diagnostics company providing next generation diagnostic solutions.

TRANSACTION HIGHLIGHTS

- Placement of 6,400,000 new shares, representing 14.3% of Biocartis’ pre-deal outstanding share capital, at an issue price of €12.50 per share, resulting in gross proceeds of €80 million

- Indications of interest received during a market sounding exercise with existing shareholders and potential new investors resulted in a c.85% covered order book for the base deal size of €60 million prior to transaction launch

- The accelerated book-building process generated strong demand from US and European Life Sciences specialist and generalist investors, on the back of which the deal size was increased to €80 million with a well oversubscribed order book 

- Genomic Health, Inc. participated in the transaction, making a strategic investment in connection with the recently announced collaboration agreement between the two parties

- Transaction proceeds are envisaged to fund the expansion of the Idylla™ test menu and applications, its sales and marketing activities, the ongoing increase of its cartridge manufacturing capacity, and working capital and other general corporate purposes

Contact

Jan De Kerpel

Transactions

No results were found